Breaking News Instant updates and real-time market news.

ANTM

Anthem

$297.84

-3.75 (-1.24%)

, HUM

Humana

$270.21

-2.3 (-0.84%)

09:01
03/26/19
03/26
09:01
03/26/19
09:01

DOJ shifts stance, backs full invalidation of Affordable Care Act, WaPo says

In a legal filing Monday with the U.S. Court of Appeals for the 5th Circuit in New Orleans, the Department of Justice revealed a significant shift in its stance and said it now backs a full invalidation of the Affordable Care Act, according to The Washington Post's Isaac Stanley-Becker. The DOJ previously has said there were grounds only to strike down the ACA's consumer protections, the report noted. Publicly traded companies in the health insurance space include CVS Health's Aetna (CVS), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Reference Link

ANTM

Anthem

$297.84

-3.75 (-1.24%)

HUM

Humana

$270.21

-2.3 (-0.84%)

CVS

CVS Health

$54.97

-1.08 (-1.93%)

CNC

Centene

$57.04

-0.09 (-0.16%)

MOH

Molina Healthcare

$144.21

-2.3 (-1.57%)

CI

Cigna

$163.71

-2.44 (-1.47%)

HNT

Health Net

$0.00

(0.00%)

UNH

UnitedHealth

$246.87

0.36 (0.15%)

WCG

WellCare

$240.87

-0.93 (-0.38%)

HCA

HCA Healthcare

$132.66

-1.96 (-1.46%)

CYH

Community Health

$4.20

-0.11 (-2.55%)

THC

Tenet

$29.04

-0.09 (-0.31%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$134.28

-1.02 (-0.75%)

  • 16

    Apr

  • 18

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 26

    Apr

  • 09

    May

ANTM Anthem
$297.84

-3.75 (-1.24%)

03/08/19
FBCO
03/08/19
NO CHANGE
Target $368
FBCO
Outperform
Anthem price target raised to $368 from $344 at Credit Suisse
Credit Suisse analyst A.J. Rice maintained an Outperform rating on Anthem and raised his price target to $368 from $344 following the company's investor day. In a research note to investors, Rice noted that the company raised its long-term core EPS growth target to 12%-15% from 8%-12%, and said EPS will grow at 20% or more for the next two years as it rolls out its new PBM, IngenioRx, and realizes the related savings. Rice raised his 2019, 2020, and 2021 EPS estimates by 10c, $1.50 and $2.35 to $19.10, $23.00, and $26.00, respectively.
03/06/19
SPHN
03/06/19
NO CHANGE
Target $350
SPHN
Overweight
Anthem has opportunity to raise long-term targets at analsyt day, says Stephens
In a preview of Anthem's investor day on Thursday, Stephens analyst Scott Fidel noted that the company's long-term adjusted EPS growth target of 8%-12% has been the most conservative among all of the publicly traded managed care companies in recent years. Given that he expects the company to achieve about 16% EPS growth through 2021 based on "several powerful unique tailwinds," Fidel sees the event as an opportunity for the company to update its long-term outlook for EPS growth. He maintains an Overweight rating and $350 price target on Anthem ahead of tomorrow's investor meeting.
03/05/19
MSCO
03/05/19
NO CHANGE
MSCO
Uncertain future of PBMs creating cloud over MCO group, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak noted that managed care stocks he covers are down an average of 10% since February 22 and "theories abound" as to why. In talks with investors, he has heard Medicare for All, drug pricing hearings and cuts to insulin prices all mentioned as potential reasons for the pressure, though "none have really stuck," Sopcak stated. However, he does believe a lack of understanding or agreement on the future of PBMs and contributions to earnings in light of HHS' proposals have "created a cloud" over the MCO group, Sopcak said. The analyst, who calls out the magnitude of the move in UnitedHealth (UNH) in particular as unwarranted, points to three potential upcoming catalysts that can "break the group's malaise" prior to earnings: Anthem's (ANTM) investor day on March 7, Humana's (HUM) investor day on March 19 and the Medicare Advantage final rate setting announcement on April 1. Other MCOs include Cigna (CI), Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG).
03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
HUM Humana
$270.21

-2.3 (-0.84%)

02/07/19
FBCO
02/07/19
NO CHANGE
Target $352
FBCO
Outperform
Humana price target lowered to $352 from $390 at Credit Suisse
Credit Suisse analyst A.J. Rice lowered his price target for Humana to $352 from $390 given the lack of visibility of HIF moratorium extension. The analyst reiterates an Outperform rating on the shares.
02/20/19
LEER
02/20/19
NO CHANGE
LEER
Market Perform
Magellan Health buyout 'reasonable' up to $90 per share, says SVB Leerink
SVB Leerink analyst Ana Gupte says a takeout of Magellan Health (MGLN) "would be reasonable" up to $90 per share based on a sum-of-the-parts analysis. The stock in midday trading is up 10% to $71.28 after Reuters reported that the company is working with Goldman Sachs to gauge takeover interest. Activist hedge fund Starboard Value, which owns a 9.8% stake in Magellan, is likely to be pushing for a management shake-out, margin turnaround and eventual takeout by a strategic buyer such as Centene (CNC), Anthem (ANTM), UnitedHealth (UNH), WellCare (WCG) or Humana (HUM), Gupte tells investors in an intraday research note. The analyst suspects strategic buyers could pay a 25%-35% premium toward a takeout price of $90 to $95 per share post a margin turnaround. Gupte has a Market Perform rating on Magellan Health.
02/20/19
SPHN
02/20/19
NO CHANGE
Target $68
SPHN
Equal Weight
Magellan's most logical strategic buyer would be in managed care, says Stephens
After Reuters reported earlier today that Magellan Health (MGLN) is exploring a sale of the company amid pressure from activist Starboard Value, Stephens analyst Scott Fidel said he thinks the most logical strategic buyer would be in the managed care sector and he compiled a list of some companies he thinks could make sense as buyers, but cautioned that his list is "certainly not exhaustive." Anthem (ANTM), Humana (HUM), UnitedHealth (UNH), WellCare (WCG) and Centene (CNC) make Fidel's list of potential strategic buyers of Magellan and he sees various scenarios where the company could be valued at as low as $51 per share to as high as $106 per share in a takeout deal. Fidel keeps an Equal Weight rating and $68 price target on shares of Magellan, which are up $7.76, or 12%, to $72.78 in afternoon trading.
CVS CVS Health
$54.97

-1.08 (-1.93%)

03/13/19
03/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Outperform at Bernstein. 2. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at Ladenburg. 3. Solaris Oilfield (SOI) initiated with a Buy at B. Riley FBR. 4. Americold Realty Trust (COLD) initiated with a Buy at Berenberg. 5. Cheniere Energy (LNG) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
03/13/19
INITIATION
Target $76

Outperform
Bernstein bullish on CVS Health, initiates coverage with an Outperform
As previously reported, Bernstein analyst Lance Wilkes started coverage of CVS Health with an Outperform rating and $76 price target. The analyst believes the current stock price does not reflect Aetna's solid MCO business and the long-term value of a care delivery strategy at retail. Further, he thinks the current valuation already reflects potential shock to PBM margins and future deterioration in the retail business.
03/12/19
BERN
03/12/19
INITIATION
Target $76
BERN
Outperform
CVS Health initiated with an Outperform at Bernstein
Bernstein initiated CVS Health with an Outperform and $76 price target.
CNC Centene
$57.04

-0.09 (-0.16%)

02/28/19
COWN
02/28/19
INITIATION
Target $77
COWN
Outperform
Centene initiated with an Outperform at Cowen
Cowen analyst Charles Rhyee initiated Centene with an Outperform rating as he likes its leading position in Medicaid and the individual exchanges, which he views as complementary businesses. He noted the strong track record in winning new business in Medicaid and in high acuity populations. Rhyee has a $77 price target on Centene shares.
MOH Molina Healthcare
$144.21

-2.3 (-1.57%)

02/28/19
02/28/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wayfair (W) initiated with a Hold at Argus. 2. Molina Healthcare (MOH) initiated with a Market Perform at Cowen. 3. Albireo Pharma (ALBO) initiated with a Buy at H.C. Wainwright. 4. Vista Outdoor (VSTO) initiated with a Buy at B. Riley FBR. 5. Atlassian (TEAM) initiated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/19
COWN
02/28/19
INITIATION
Target $145
COWN
Market Perform
Molina Healthcare initiated with a Market Perform at Cowen
Cowen analyst Charles Rhyee initiated Molina Healthcare with a Market Perform rating and $145 price target, citing his view of the "meaningful" binary risk he sees in the near-term from the Texas RFPs. Rhyee sees greater downside risk than upside potential as he believes Molina shares largely reflect the company maintaining its current share, he tells investors.
02/13/19
MSCO
02/13/19
NO CHANGE
Target $192
MSCO
Overweight
Molina Healthcare pullback a buying opportunity, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak said investor concerns about Molina Healthcare's 2019 topline growth are missing the significant upside to earnings power that he sees from an incremental $350M in cost cutting beyond 2019, RFP opportunities in Medicaid and the opportunity to expand its exchange footprint. Sopcak, who thinks the company's investor day meeting in late May could bring topline opportunities into greater focus, views the 5% pullback in Molina shares as a buying opportunity and keeps an Overweight rating and $192 price target on the stock.
CI Cigna
$163.71

-2.44 (-1.47%)

02/19/19
SBSH
02/19/19
NO CHANGE
SBSH
Buy
Citi confident in Cigna earnings target after CEO meetings
After hosting investor meetings with CEO David Cordani, Citi analyst Ralph Giacobbe has confidence in Cigna's $20-$21 earnings per share target for 2021. The analyst continues to view Cigna as a "compelling story and stock." The company is his top pick and highest conviction name. He keeps a Buy rating on the name.
02/04/19
PIPR
02/04/19
NO CHANGE
Target $227
PIPR
Overweight
Piper Jaffray likes the set-up for Cigna shares in 2019
Piper Jaffray analyst Sarah James likes the set-up for Cigna (CI) in 2019. The company has built 25c-50c of conservatism into its earnings guidance and has potential for a "strong" 2020 driven by better cost trend control, its specialty business, and working down the $200M stranded overhead cost from Anthem's departure, James tells investors in a research note. Further, the analyst does not have the pharmacy benefits manager volume coming back in-house from UnitedHealth (UNH) in her numbers yet, which she sees as "likely upside to 2021." The analyst also believes Cigna "screens as cheap" at 10.6 times expected 2020 earnings. James reiterates an Overweight rating on the shares with a $227 price target.
HNT Health Net
$0.00

(0.00%)

UNH UnitedHealth
$246.87

0.36 (0.15%)

03/14/19
PIPR
03/14/19
NO CHANGE
Target $47
PIPR
Overweight
Myriad Genetics on cusp of positive news events, says Piper Jaffray
After hosting investor meetings with management, Piper Jaffray analyst William Quirk believes Myriad Genetics (MGN) is "on the cusp of several positive news events." Management is optimistic that they could get a draft local coverage determinations for expanded GeneSight coverage by Medicare, Quirk tells investors in a research note. He expects visibility on this by late March. Further, the analyst believes Counsyl's April 1 in-network status with UnitedHealth (UNH) could lead to $6M-$7M upside to his current Q4 estimates. Quirk reiterates an Overweight rating on Myriad Genetics with a $47 price target.
02/28/19
BARD
02/28/19
NO CHANGE
Target $80
BARD
Outperform
Teladoc Q4 results solid, better than headline, says Baird
Baird analyst Matthew Gillmor said Teladoc's (TDOC) Q4 results were solid and better than the headlines suggest. He believes the selloff is due to guidance and perhaps some disappointment with UnitedHealth (UNH), but he said management's explanations around revenue guidance were very credible. He was encouraged with the growth related investments and he would be a buyer of the shares on the weakness. Gillmor reiterated his Outperform rating and $80 price target on Teladoc shares.
WCG WellCare
$240.87

-0.93 (-0.38%)

03/07/19
SPHN
03/07/19
NO CHANGE
Target $305
SPHN
Overweight
WellCare's new disclosures should help level-set PDP contribution, says Stephens
Stephens analyst Scott Fidel said WellCare shares have recently been "caught up in the dragnet of anxiety" hitting the MCO group around the potential impact of the HHS rebate proposal on the Medicare and Medicaid markets, along with general uncertainty around "Medicare for All," the 2020 presidential elections and potential future changes to the existing PBM pricing/profit model. Given the shifting market sentiment, WellCare gave "some new disclosures at an investor conference that we have never seen them give us before," noted Fidel, who reports that the company's CFO said that Medicare PDP will only account for about 7.5% of 2019 adjusted EPS. Some recent Street estimates have assumed PDP was driving upwards of 20% or higher of overall EPS, according to Fidel, who said this new disclosure "helps to level-set the actual contribution from this business." Fidel also noted that WellCare's CFO said he is "very pleased" with the performance of its new PDP plans that have generated significant enrollment growth in 2019. Fidel keeps an Overweight rating and $305 price target on WellCare shares.
02/28/19
COWN
02/28/19
INITIATION
Target $335
COWN
Outperform
WellCare initiated with an Outperform at Cowen
Cowen analyst Charles Rhyee initiated WellCare with an Outperform rating. The analyst noted the shares trade at a premium, which he believes is justified given visibility into multi-year growth drivers such including Meridian, organic wins such as North Carolina, the addition of Aetna's prescription drug lives in 2020, and PBM re-contracting for 2021. Ryhee has a $335 price target on WellCare shares.
HCA HCA Healthcare
$132.66

-1.96 (-1.46%)

01/24/19
BARD
01/24/19
NO CHANGE
Target $155
BARD
Outperform
HCA Healthcare elevated to Fresh Pick at Baird
Baird analyst Matthew Gillmor elevated HCA Healthcare (HCA) to Fresh Pick ahead of its Q4 report. The analyst said recent commentary from UnitedHealth (UNH) and Johnson & Johnson (JNJ) suggest Q4 patient volumes remain solid, which he thinks will translate into EBITDA upside for HCA. Gillmor reiterated his Outperform rating and $155 price target on HCA Healthcare shares.
01/30/19
LEER
01/30/19
NO CHANGE
Target $175
LEER
Outperform
HCA Healthcare price target raised to $175 from $160 at Leerink
Leerink analyst Ana Gupte raised her price target for HCA Healthcare to $175 from $160 as she has continued high conviction on it after a "solid" Q4 and 2019 guidance, increase in share repurchase authorization and dividend yield. The analyst reiterates an Outperform rating on the shares.
01/30/19
OPCO
01/30/19
NO CHANGE
Target $150
OPCO
Outperform
HCA Healthcare price target raised to $150 from $142 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for HCA Healthcare to $150 from $142 following quarterly results. The analyst reiterates an Outperform rating on the shares.
01/30/19
RHCO
01/30/19
NO CHANGE
Target $175
RHCO
Buy
HCA Healthcare price target raised to $175 from $165 at SunTrust
SunTrust analyst David MacDonald raised his price target on HCA Healthcare to $175 and kept his Buy rating after the company's "impressive" quarter marked by "solid" organic volumes, robust acuity and price, and "superb" cash flows". The analyst also points to HCA Healthcare's "sizable capex pipeline" that targets areas including IT improvements, expanded service offerings, and capacity expansion. MacDonald expects the company to continue to widen its competitive moat through its "robust cash flow and massive balance sheet".
CYH Community Health
$4.20

-0.11 (-2.55%)

11/07/18
MSCO
11/07/18
NO CHANGE
MSCO
Split Congress 'best outcome' for MCOs and hospitals, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak contends that the Democratic party retaking the majority in the House of Representatives and Republicans retaining the Senate is the "best outcome" for Managed Care Organizations and hospitals, stating that he now sees another attempt at a repeal/replace of the Affordable Care Act as "off the table." The split Congress could also lower the volume on the "Medicare for All" debate given a lack of mandate from either the Democratic or Republican party, Sopcak tells investors. The election results remove a key overhang for Centene (CNC) and Molina (MOH), which he views as most exposed to the ACA marketplace, and to a lesser extent the hospitals, Sopcak added. With ACA repeal/replace off the table, and given the longer term potential upside from Medicaid expansion in Utah and Idaho as expansion ballot initiatives appear to be passing in both states, Sopcak said Molina is emerging as his top pick in the space heading into the final weeks of 2018. Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
11/15/18
UBSW
11/15/18
INITIATION
Target $2
UBSW
Sell
Community Health initiated with a Sell at UBS
UBS analyst Whit Mayo initiated Community Health with a Sell rating and a price target of $2.
11/15/18
UBSW
11/15/18
INITIATION
UBSW
HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS
UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.
12/28/18
PIPR
12/28/18
NO CHANGE
PIPR
Piper says buy Centene, sell Community Health if recession were to occur
After performing a recession risk/reward for Hospitals and Managed Care Organizations, Piper Jaffray analyst Sarah James recommends buying Centene (CNC) and selling Community Health Systems (CYH) if a recession were to occur. The analyst says that with some economists calling for a recession in 2019, she dug into the potential impacts across the hospital and insurance sector. For hospitals, consumer surveys point to economic outlook impacting decisions to receive services, James tells investors in a research note. On the other hand, insurers are a "natural defensive sector in a recession," adds the analyst. As such, in a recession James would be adding exposure to insurers and lightening hospitals.
THC Tenet
$29.04

-0.09 (-0.31%)

02/27/19
RAJA
02/27/19
NO CHANGE
Target $47
RAJA
Outperform
Tenet price target raised to $47 from $37 at Raymond James
01/14/19
SPHN
01/14/19
INITIATION
Target $23
SPHN
Equal Weight
Tenet initiated with an Equal Weight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Tenet with an Equal Weight rating and $23 price target, stating that the market's increased volatility could further complicate its efforts to sell Conifer at an attractive valuation. The persistent underperformance of the hospital segment and ongoing divestiture program make it hard to forecast more than low-single digit annual revenue and EBITDA growth, said Fidel.
01/03/19
DBAB
01/03/19
INITIATION
Target $20
DBAB
Hold
Tenet initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Pito Chickering started Tenet Healthcare with a Hold rating and $20 price target. The analyst initiated coverage on Healthcare Facilities with a constructive view saying the sector is "relatively defensive" in slowing business cycles and that company cash flows "provide downside protection in volatile markets."
LPNT LifePoint
$0.00

(0.00%)

07/24/18
BARD
07/24/18
DOWNGRADE
Target $65
BARD
Neutral
LifePoint downgraded to Neutral from Outperform at Baird
Baird analyst Matthew Gillmor downgraded LifePoint Health (LPNT) to Market Perform after the company agreed to be acquired by Apollo Global (APO) affiliates for $65 per share.
07/24/18
FBCO
07/24/18
NO CHANGE
Target $65
FBCO
Neutral
LifePoint price target raised to $65 from $58 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for LifePoint (LPNT) to $65 from $58 to reflect deal price after the company agreed to be acquired by Apollo Global (APO) affiliates for $65 per share. The analyst reiterates a Neutral rating on LifePoint shares.
07/24/18
BMOC
07/24/18
NO CHANGE
Target $62
BMOC
Market Perform
LifePoint price target raised to $62 from $51 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on LifePoint (LPNT) to $62 and kept his Market Perform rating after the proposed transaction for the company to be taken private by the Apollo Global (APO) affiliate RCCH HealthCare Partners at $65 per share. The analyst says his price target reflects the acquisition price blended with some uncertainty regarding the deal, even as he views the terms of the offer as attractive to LifePoint shareholders against the"backdrop of reimbursement and volume pressures that challenge acute care hospitals".
UHS Universal Health
$134.28

-1.02 (-0.75%)

03/05/19
BMOC
03/05/19
NO CHANGE
Target $146
BMOC
Market Perform
Universal Health price target raised to $146 from $130 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on Universal Health to $146, citing its above-consensus outlook for 2019 announced last week. The analyst states that while the company remains "reliant on continued acute-care strength", the forecast has given him a better "view of expectations now that management has backed away from promises of near-term improvement in the behavioral side, which should strengthen its credibility." Borsch is keeping his Market Perform rating on Universal Health however, noting that its current valuation of enterprise value to EBITDA at 9.1-times is "fair" and implies only modest stock price upside.
03/04/19
03/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) downgraded to Underweight from Equal Weight at Barclays with analyst Matthew McClintock saying he believes there is "limited, if any," visibility into a potential inflection point towards improving traffic trends. 2. Hawaiian Holdings (HA) downgraded to Sell from Hold at Deutsche Bank with analyst Michael Linenberg citing increased competition given Southwest Airlines' (LUV) plans for inter-island flying. 3. Enbridge (ENB) downgraded to In Line from Outperform at Evercore ISI and to Sector Perform from Outperform at Scotiabank and National Bank. 4. SunTrust (STI) downgraded to Neutral from Buy at UBS with analyst Saul Martinez saying his Buy thesis no longer holds due to the proposed merger with BB&T (BBT). 5. Universal Health (UHS) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying while he does not have a "new active negative thesis" on the shares, he finds the stock "relatively fairly valued with limited catalysts." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/04/19
JPMS
03/04/19
DOWNGRADE
Target $147
JPMS
Neutral
Universal Health downgraded to Neutral on valuation at JPMorgan
JPMorgan analyst Gary Taylor downgraded Universal Health Services to Neutral from Overweight with an unchanged price target of $147. The analyst says that while he does not have a "new active negative thesis" on the shares, he finds the stock "relatively fairly valued with limited catalysts." Universal Health's valuation continues to reflect a stronger secular EBITDA growth outlook than the company has been able to deliver over the last three years or is implied in 2019 guidance, Taylor tells investors in a research note.
03/04/19
JPMS
03/04/19
DOWNGRADE
Target $147
JPMS
Neutral
Universal Health downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Gary Taylor downgraded Universal Health Services to Neutral with an unchanged price target of $147.

TODAY'S FREE FLY STORIES

02:50
05/21/19
05/21
02:50
05/21/19
02:50
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

02:10
05/21/19
05/21
02:10
05/21/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

OXY

Occidental Petroleum

$53.49

0.74 (1.40%)

21:25
05/20/19
05/20
21:25
05/20/19
21:25
Downgrade
Occidental Petroleum rating change at Wells Fargo »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TIGR

UP Fintech

$5.63

-0.14 (-2.43%)

20:41
05/20/19
05/20
20:41
05/20/19
20:41
Hot Stocks
Interactive Brokers Group discloses 7.6% stake in UP Fintech »

IBGI acquired beneficial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$52.95

-0.08 (-0.15%)

, HD

Home Depot

$190.87

-1.66 (-0.86%)

20:25
05/20/19
05/20
20:25
05/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$52.95

-0.08 (-0.15%)

HD

Home Depot

$190.87

-1.66 (-0.86%)

AZO

AutoZone

$978.78

-5.21 (-0.53%)

KSS

Kohl's

$62.95

-0.68 (-1.07%)

EV

Eaton Vance

$37.27

-0.535 (-1.42%)

JCP

J.C. Penney

$1.15

0.01 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 23

    May

  • 24

    May

  • 29

    May

  • 04

    Jun

  • 11

    Jun

JCOM

j2 Global

$86.48

-0.23 (-0.27%)

20:22
05/20/19
05/20
20:22
05/20/19
20:22
Hot Stocks
j2 Global CFO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

ATTO

Atento

$3.24

-0.14 (-4.14%)

19:58
05/20/19
05/20
19:58
05/20/19
19:58
Earnings
Atento sees FY19 revenue flat to up single digits »

The company sees sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

ATTO

Atento

$3.24

-0.14 (-4.14%)

19:57
05/20/19
05/20
19:57
05/20/19
19:57
Earnings
Atento reports Q1 recurring EPS (6c), consensus 10c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

ITCB

Itau Corpbanca

$12.95

(0.00%)

19:38
05/20/19
05/20
19:38
05/20/19
19:38
Hot Stocks
Itau Corpbanca dissolves subsidiary Corplegal »

Itau Corpbanca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

19:36
05/20/19
05/20
19:36
05/20/19
19:36
Recommendations
Ocular Therapeutix analyst commentary at Piper Jaffray »

Ocular Therapeutix price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

YGYI

Youngevity

$6.57

0.13 (2.02%)

, QFIN

360 Finance

$16.46

0.71 (4.51%)

18:55
05/20/19
05/20
18:55
05/20/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

YGYI

Youngevity

$6.57

0.13 (2.02%)

QFIN

360 Finance

$16.46

0.71 (4.51%)

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

TRIP

TripAdvisor

$44.93

-0.07 (-0.16%)

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

KR

Kroger

$24.04

-0.18 (-0.74%)

SNAP

Snap

$11.19

-0.3 (-2.61%)

NDSN

Nordson

$130.42

-4.8 (-3.55%)

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

SWI

SolarWinds

$19.16

0.04 (0.21%)

MRCY

Mercury Systems

$72.85

-0.11 (-0.15%)

VNE

Veoneer

$18.89

0.02 (0.11%)

GH

Guardant Health

$78.29

2.13 (2.80%)

CVNA

Carvana

$67.17

-0.935 (-1.37%)

INSM

Insmed

$28.08

-1.08 (-3.70%)

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 18

    Jun

  • 23

    Jun

  • 10

    Nov

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    Jun

TOL

Toll Brothers

$37.52

-0.88 (-2.29%)

18:47
05/20/19
05/20
18:47
05/20/19
18:47
Hot Stocks
Toll Brothers acquires Sharp Residential, terms not disclosed »

Toll Brothers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

18:45
05/20/19
05/20
18:45
05/20/19
18:45
General news
Breaking General news story  »

Federal Reserve Chairman…

TTWO

Take-Two

$102.94

-3.82 (-3.58%)

18:44
05/20/19
05/20
18:44
05/20/19
18:44
Hot Stocks
Take-Two CEO: Our job is to excite customers »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Nov

AAL

American Airlines

$30.96

-0.8 (-2.52%)

18:40
05/20/19
05/20
18:40
05/20/19
18:40
Periodicals
American Air asks court to halt alleged mechanics unions' slowdown, Reuters says »

American Airlines has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

  • 12

    Jun

  • 12

    Jun

LWAY

Lifeway Foods

$2.75

0.05 (1.85%)

18:38
05/20/19
05/20
18:38
05/20/19
18:38
Earnings
Lifeway Foods reports Q1 EPS (2c) vs. 0c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WHLR

Wheeler REIT

$2.25

0.025 (1.13%)

18:31
05/20/19
05/20
18:31
05/20/19
18:31
Hot Stocks
Wheeler REIT chairman John Sweet to resign »

Wheeler Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$101.54

0.66 (0.65%)

, TGT

Target

$72.10

1.22 (1.72%)

18:03
05/20/19
05/20
18:03
05/20/19
18:03
Periodicals
Judge says Walmart, Target, Bed Bath must face suits over cotton, Reuters says »

U.S. District Judge…

WMT

Walmart

$101.54

0.66 (0.65%)

TGT

Target

$72.10

1.22 (1.72%)

BBBY

Bed Bath & Beyond

$14.48

-0.525 (-3.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 15

    Aug

  • 13

    Nov

QFIN

360 Finance

$16.46

0.71 (4.51%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Earnings
360 Finance reports Q1 net income $117.5M, up 382% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

MRK

Merck

$78.86

0.15 (0.19%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Hot Stocks
Merck falls after Keytruda trial does not meet OS primary endpoint »

Shares of Merck have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

PRIM

Primoris

$20.26

-0.08 (-0.39%)

17:55
05/20/19
05/20
17:55
05/20/19
17:55
Hot Stocks
Primoris director sells 99.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

, LM

Legg Mason

$35.68

0.295 (0.83%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
BNY Mellon announces Ed Garden to step down from board of directors »

BNY Mellon (BK) announced…

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

LM

Legg Mason

$35.68

0.295 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DHR

Danaher

$130.33

-0.81 (-0.62%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
VP of Danaher Angela Lalor sells over $408K in company shares »

VP of Danaher Angela…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 07

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

17:43
05/20/19
05/20
17:43
05/20/19
17:43
Periodicals
Judge dismisses Trump request to block accounting subpoena, WSJ says »

U.S. District Judge Amit…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$35.68

0.295 (0.83%)

17:40
05/20/19
05/20
17:40
05/20/19
17:40
Hot Stocks
Legg Mason names Nelson Peltz, Ed Garden to board of directors »

Legg Mason announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.